You are here

Enrollment in Clinical Studies for Angiogenic Gene Therapy Candidate Stopped

BERLIN -- January 30, 2004 -- Schering AG Germany (FSE: SCH, NYSE: SHR) announced today that it has stopped enrollment in its Phase IIB/III clinical studies for Ad5FGF-4, its investigational, non-surgical angiogenic gene therapy product being developed for the treatment of patients with stable exertional angina due to coronary artery disease.

The company’s analysis of the interim data of one of the studies has led it to conclude that the studies, as currently designed, will not provide sufficient evidence of efficacy to warrant continued enrollment. The company is instructing investigators to stop patient enrollment. All patients who have already been treated will continue to be evaluated.

Each study is being monitored by an independent Data Safety Monitoring Board (DSMB). No evidence of important safety concerns was found.

Schering AG continues to evaluate and explore the potential of this highly innovative technology.

Source: Schering AG

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly